Imagine trading a 2.3-hour hospital infusion for a quick injection that takes less than 10 minutes. That's the potential shift a new study is exploring for people with advanced solid tumors. Researchers tested a new way to give the cancer drug amivantamab—as an injection under the skin (subcutaneously) instead of through a vein (intravenously).
The early-phase trial involved 158 patients. The big wins were about making treatment easier. The injection method dramatically cut the time patients spent receiving the drug. It also led to fewer and less severe infusion-related reactions—the chills, fevers, or breathing problems that can happen with IV drugs. The study also figured out potential dosing schedules for future testing.
Doctors saw that the injection's safety profile and early signs of how well it worked against cancer looked consistent with what they know from the IV version. The most common side effects were related to the drug's expected action on cancer cells. It's crucial to remember this is a phase Ib study, a first step in testing this new delivery method. The comparison to the IV treatment was made against historical data, not by randomly assigning patients to one method or the other in the same trial.
This research points toward a future where cancer treatment could be far less disruptive to daily life. The findings on time and safety are encouraging for patient comfort. However, larger, more direct comparisons are needed to fully understand how the injection stacks up against the standard IV treatment in controlling cancer over the long term.
